FILED PURSUANT TO SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SECTION 30(h) OF THE INVESTMENT COMPANY ACT OF 1940

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
Oosthuizen Johannes Jacobus
(R/m) 126 LINCOLN AVENUE
RAHWAY, NJ 07065

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
10/28/2022

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer
(See Instruction 1(b)).

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Trans. Date</th>
<th>Code</th>
<th>V</th>
<th>(A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/28/2022</td>
<td>S</td>
<td>3633</td>
<td>D</td>
<td>$100.2105</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10880.881</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/30/2022</td>
<td>M</td>
<td>913</td>
<td>A</td>
<td>$100.77</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11793.881</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/30/2022</td>
<td>F</td>
<td>450</td>
<td>D</td>
<td>$100.77</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11343.881</td>
</tr>
</tbody>
</table>

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Derivative Security</th>
<th>Trans. Date</th>
<th>Code</th>
<th>(A) or (D)</th>
<th>Exercisable and Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>10/30/2022</td>
<td>M</td>
<td>913</td>
<td>10/30/2021</td>
<td>Common Stock</td>
<td>913</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

(1) Holdings include shares acquired in dividend reinvestment transactions.

(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2021, 10/30/2022 and 10/30/2023.

Reporting Owners

Reporting Owner Name / Address
Oosthuizen Johannes Jacobus
MERCK & CO., INC.
126 LINCOLN AVENUE
RAHWAY, NJ 07065

Relationships
Director 10% Owner Officer Other
President, U.S. Market

Signatures

/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen
11/1/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.